Epidermal growth factor receptor status and Notch inhibition in non-small cell lung cancer cells

Journal of Biomedical Science

Volumn 22, Issue 1, 2015, Pages

  Giannopoulou, Efstathia ^a   Nikolakopoulos, Achilleas ^a   Kotsirilou, Dimitra ^a,b   Lampropoulou, Angeliki ^a,b   Raftopoulou, Sofia ^c   Papadimitriou, Evangelia ^b   Theocharis, Achilleas D ^b   Makatsoris, Thomas ^a   Fasseas, Konstantinos ^c   Kalofonos, Haralabos P ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

^c AGRICULTURAL UNIVERSITY OF ATHENS   (Greece)

Author keywords

Apoptosis; Autophagy; Cell cycle arrest; Epidermal growth factor receptor; Non small cell lung cancer cells; Notch intracellular domain

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GAMMA SECRETASE INHIBITOR; NOTCH RECEPTOR; UNCLASSIFIED DRUG; [N (3, 5 DIFLUOROPHENACETYL) 1 ALANYL]PHENYLGLYCINE TERT BUTYL ESTER; EGFR PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

A-549 CELL LINE; ARTICLE; CANCER CELL LINE; CELL COUNT; CELL DEATH; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; H 23 CELL LINE; HCC 827 CELL LINE; HUMAN; HUMAN CELL; MUTATION; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; GENETICS; LUNG TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; HUMANS; LUNG NEOPLASMS; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 84944706454     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/s12929-015-0196-1     Document Type: Article

References (42)

1. D'Addario G, Felip E. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20 Suppl 4:68-70.
2. Hammerschmidt S, Wirtz H. Lung cancer: current diagnosis and treatment. Dtsch Arztebl Int. 2009;106(49):809-18. quiz 19-20.
3. Reade CA, Ganti AK. EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab. Biogeosciences. 2009;3:215-24.
4. Aita M, Fasola G, Defferrari C, Brianti A, Bello MG, Follador A, et al. Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer. Crit Rev Oncol Hematol. 2008;68(3):183-96.
5. Adamo V, Franchina T, Adamo B, Denaro N, Gambadauro P, Chiofalo G, et al. Gefitinib in lung cancer therapy: clinical results, predictive markers of response and future perspectives. Cancer Biol Ther. 2009;8(3):206-12.
6. Scagliotti G, Govindan R. Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer. Oncologist. 2010;15(5):436-46.
7. Pennell NA, Lynch Jr TJ. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC. Oncologist. 2009;14(4):399-411.
8. Andre F, Le Chevalier T, Soria JC. Her2-neu: A target in lung cancer? Ann Oncol. 2004;15(1):3-4.
9. Mahalingam D, Mita A, Mita MM, Nawrocki ST, Giles FJ. Targeted therapy for advanced non-small cell lung cancers: historical perspective, current practices, and future development. Curr Probl Cancer. 2009;33(2):73-111.
10. Miele L, Golde T, Osborne B. Notch signaling in cancer. Curr Mol Med. 2006;6(8):905-18.
11. Collins BJ, Kleeberger W, Ball DW. Notch in lung development and lung cancer. Semin Cancer Biol. 2004;14(5):357-64.
12. Westhoff B, Colaluca IN, D'Ario G, Donzelli M, Tosoni D, Volorio S, et al. Alterations of the Notch pathway in lung cancer. Proc Natl Acad Sci U S A. 2009;106(52):22293-8.
13. Axelson H. Notch signaling and cancer: emerging complexity. Semin Cancer Biol. 2004;14(5):317-9.
14. Wang NJ, Sanborn Z, Arnett KL, Bayston LJ, Liao W, Proby CM, et al. Loss-offunction mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proc Natl Acad Sci U S A. 2011;108(43):17761-6.
15. Li C, Zhang Y, Lu Y, Cui Z, Yu M, Zhang S, et al. Evidence of the cross talk between Wnt and Notch signaling pathways in non-small-cell lung cancer (NSCLC): Notch3-siRNA weakens the effect of LiCl on the cell cycle of NSCLC cell lines. J Cancer Res Clin Oncol. 2011;137(5):771-8.
16. Baumgart A, Seidl S, Vlachou P, Michel L, Mitova N, Schatz N, et al. ADAM17 regulates epidermal growth factor receptor expression through the activation of Notch1 in non-small cell lung cancer. Cancer Res. 2010;70(13):5368-78.
17. Konishi J, Yi F, Chen X, Vo H, Carbone DP, Dang TP. Notch3 cooperates with the EGFR pathway to modulate apoptosis through the induction of bim. Oncogene. 2010;29(4):589-96.
18. Li Y, Burns JA, Cheney CA, Zhang N, Vitelli S, Wang F, et al. Distinct expression profiles of Notch-1 protein in human solid tumors: Implications for development of targeted therapeutic monoclonal antibodies. Biogeosciences. 2010;4:163-71.
19. Dai J, Ma D, Zang S, Guo D, Qu X, Ye J, et al. Cross-talk between Notch and EGFR signaling in human breast cancer cells. Cancer Invest. 2009;27(5):533-40.
20. Wang Z, Li Y, Ahmad A, Azmi AS, Banerjee S, Kong D, et al. Targeting Notch signaling pathway to overcome drug resistance for cancer therapy. Biochim Biophys Acta. 2010;1806(2):258-67.
21. Doroquez DB, Rebay I. Signal integration during development: mechanisms of EGFR and Notch pathway function and cross-talk. Crit Rev Biochem Mol Biol. 2006;41(6):339-85. doi:10.1080/10409230600914344.
22. Baker AT, Zlobin A, Osipo C. Notch-EGFR/HER2 Bidirectional Crosstalk in Breast Cancer. Front in oncol. 2014;4:360. doi:10.3389/fonc.2014.00360.
23. Xie M, He CS, Wei SH, Zhang L. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo. Eur J Cancer. 2013;49(16):3559-72. doi:10.1016/j.ejca.2013.07.007.
24. Koutras A, Giannopoulou E, Kritikou I, Antonacopoulou A, Evans TR, Papavassiliou AG, et al. Antiproliferative effect of exemestane in lung cancer cells. Mol Cancer. 2009;8:109.
25. Kuwada SK, Scaife CL, Kuang J, Li X, Wong RF, Florell SR, et al. Effects of trastuzumab on epidermal growth factor receptor-dependent and -independent human colon cancer cells. Int J Cancer. 2004;109(2):291-301.
26. Furugaki K, Iwai T, Moriya Y, Harada N, Fujimoto-Ouchi K. Loss of an EGFRamplified chromosome 7 as a novel mechanism of acquired resistance to EGFR-TKIs in EGFR-mutated NSCLC cells. Lung Cancer. 2014;83(1):44-50. doi:10.1016/j.lungcan.2013.10.003.
27. Cragg MS, Kuroda J, Puthalakath H, Huang DC, Strasser A. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med. 2007;4(10):1681-9. doi:10.1371/journal.pmed.0040316. discussion 90.
28. He Y, Mo Z, Xue Z, Fang Y. Establish a flow cytometric method for quantitative detection of Beclin-1 expression. Cytotechnology. 2013;65(4):481-9. doi:10.1007/s10616-012-9503-9.
29. Giannopoulou E, Antonacopoulou A, Matsouka P, Kalofonos HP. Autophagy: novel action of panitumumab in colon cancer. Anticancer Res. 2009;29(12):5077-82.
30. Chen Y, De Marco MA, Graziani I, Gazdar AF, Strack PR, Miele L, et al. Oxygen concentration determines the biological effects of NOTCH-1 signaling in adenocarcinoma of the lung. Cancer Res. 2007;67(17):7954-9.
31. Yin L, Velazquez OC, Liu ZJ. Notch signaling: emerging molecular targets for cancer therapy. Biochem Pharmacol. 2010;80(5):690-701.
32. Mazzone M, Selfors LM, Albeck J, Overholtzer M, Sale S, Carroll DL, et al. Dose-dependent induction of distinct phenotypic responses to Notch pathway activation in mammary epithelial cells. Proc Natl Acad Sci U S A. 2010;107(11):5012-7. doi:10.1073/pnas.1000896107.
33. Hu J, Zhu X, Lu Q. Antiproliferative effects of gamma-secretase inhibitor, a Notch signalling inhibitor, in multiple myeloma cells and its molecular mechanism of action. J Int Med Res. 2013;41(4):1017-26. doi:10.1177/0300060513485912.
34. Zang S, Ji C, Qu X, Dong X, Ma D, Ye J, et al. A study on Notch signaling in human breast cancer. Neoplasma. 2007;54(4):304-10.
35. Cao H, Hu Y, Wang P, Zhou J, Deng Z, Wen J. Down-regulation of Notch receptor signaling pathway induces caspase-dependent and caspaseindependent apoptosis in lung squamous cell carcinoma cells. APMIS. 2012;120(6):441-50. doi:10.1111/j.1600-0463.2011.02825.x.
36. Liu JJ, Lin M, Yu JY, Liu B, Bao JK. Targeting apoptotic and autophagic pathways for cancer therapeutics. Cancer Lett. 2011;300(2):105-14. doi:10.1016/j.canlet.2010.10.001.
37. Barth JM, Hafen E, Kohler K. The lack of autophagy triggers precocious activation of Notch signaling during Drosophila oogenesis. BMC Dev Biol. 2012;12:35. doi:10.1186/1471-213X-12-35.
38. Furugaki K, Iwai T, Shirane M, Kondoh K, Moriya Y, Mori K. Schedule-dependent antitumor activity of the combination with erlotinib and docetaxel in human non-small cell lung cancer cells with EGFR mutation, KRAS mutation or both wild-type EGFR and KRAS. Oncol Rep. 2010;24(5):1141-6.
39. Kang JH, Lee EH, Park SW, Chung IY. MUC5AC expression through bidirectional communication of Notch and epidermal growth factor receptor pathways. J Immunol. 2011;187(1):222-9. doi:10.4049/jimmunol.1003606.
40. Purow BW, Sundaresan TK, Burdick MJ, Kefas BA, Comeau LD, Hawkinson MP, et al. Notch-1 regulates transcription of the epidermal growth factor receptor through p53. Carcinogenesis. 2008;29(5):918-25. doi:10.1093/carcin/bgn079.
41. Osipo C, Patel P, Rizzo P, Clementz AG, Hao L, Golde TE, et al. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor. Oncogene. 2008;27(37):5019-32. doi:10.1038/onc.2008.149.
42. Diaz B, Yuen A, Iizuka S, Higashiyama S, Courtneidge SA. Notch increases the shedding of HB-EGF by ADAM12 to potentiate invadopodia formation in hypoxia. J Cell Biol. 2013;201(2):279-92. doi:10.1083/jcb.201209151.